Analystreport

Horizon Therapeutics Public Limited (NASDAQ: HZNP) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $103.00 price target on t

Horizon Therapeutics Public Limited Company - Ordinary Shares  (HZNP) 
Last horizon therapeutics public limited company - ordinary shares earnings: 2/26 07:00 am Check Earnings Report